Although prior studies in animal models have reported a positive impact of SGLT2 inhibitors on body fat distribution and NAFLD severity [29,30], human studies have reported inconsistent findings. This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatotic liver disease.